Traders should monitor for potential secondary sales by institutional holders, which could increase near-term share supply and pressure stock price; however, no immediate dilution or capital raise by the company is occurring.
LYEL drugs
LYEL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 15 $23.84entry
- T+1 · 7mo ago −0.59%α −0.84% · $23.70
- T+5 · 7mo ago +3.94%α +2.30% · $24.78
- T+20 · 6mo ago −19.25%α −25.30% · $19.25
- T+60 · 4mo ago −37.04%α −45.18% · $15.01
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma's S-3 shelf registration has become effective, allowing the resale of up to 1,952,360 shares by selling stockholders. The company will not receive proceeds from any sales under this registration.
Key Facts
- S-3 shelf registration effective as of April 14, 2026
- Enables resale of 1,952,360 shares of common stock by selling stockholders
- Shares were acquired in a private placement on March 6, 2026, at $25.61 per share
- Company will not receive any proceeds from resales under this registration
- Selling stockholders include institutional investors such as ARCH Venture Fund, Gates Frontier, and Explore Investments
Financial Impact
No direct financial impact to Lyell Immunopharma, no proceeds from resales
Risk Factors
- Potential for increased share volatility if selling stockholders offload large positions
- Perception of negative sentiment if early investors begin exiting positions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001185 |
| Document: 9999999995-26-001185-index.html | 9999999995-26-001185 |
| Document: 9999999995-26-001185.txt | 9999999995-26-001185 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers